Moderna (NASDAQ:MRNA) Hits New 1-Year Low – Here’s Why

Moderna, Inc. (NASDAQ:MRNA)’s stock price hit a new 52-week low during trading on Thursday . The company traded as low as $57.32 and last traded at $57.45, with a volume of 310765 shares trading hands. The stock had previously closed at $58.86.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MRNA. Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 target price on shares of Moderna in a report on Thursday, September 19th. Leerink Partners lowered their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Piper Sandler decreased their price objective on Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, September 13th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $100.44.

Moderna Stock Up 2.6 %

The firm has a 50-day moving average of $74.02 and a two-hundred day moving average of $106.70. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $22.41 billion, a PE ratio of -3.79 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period last year, the company posted ($3.62) earnings per share. The firm’s revenue was down 29.9% compared to the same quarter last year. On average, equities research analysts forecast that Moderna, Inc. will post -9.85 EPS for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the transaction, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00. Following the sale, the president now owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,184 shares of company stock valued at $7,464,331 over the last three months. 15.70% of the stock is owned by company insiders.

Institutional Trading of Moderna

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Moderna by 22.6% in the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock worth $3,372,058,000 after purchasing an additional 6,248,623 shares in the last quarter. Wellington Management Group LLP grew its stake in Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after purchasing an additional 1,614,460 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in Moderna by 42.9% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after purchasing an additional 463,960 shares in the last quarter. Nikko Asset Management Americas Inc. grew its stake in Moderna by 156.9% in the first quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock worth $79,044,000 after purchasing an additional 453,004 shares in the last quarter. Finally, Intech Investment Management LLC grew its stake in Moderna by 1,212.9% in the first quarter. Intech Investment Management LLC now owns 330,805 shares of the company’s stock worth $35,251,000 after purchasing an additional 305,609 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.